A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback